Effect of Rivaroxaban on Prevention of Thrombus After Stent Implantation in Different Anatomic Types of Nonthrombotic Iliac Vein Compression Syndrome
To investigate the efficacy of rivaroxaban in the prevention of thrombosis after stent implantation in different anatomical types of non-thrombotic iliac vein compression syndrome. Compared with the control group, the experimental group was significantly better than the control group (P<0.05). The incidence of bleeding events in the experimental group was significantly lower than that in the control group (P < 0.05). The VCSS scores of patients with acute thrombosis were further analyzed. The VCSS scores of the two groups were significantly different (P<0.05). The prognosis of the experimental group was better than that of the control group. The quality of life scores of the two groups were not statistically significant (P>0.05). After treatment, the quality of life scores of the experimental group were higher than the control group, the difference was statistically significant (P<0.05). Conclusion: Rivaroxaban did not increase the risk of overall bleeding, and the curative effect was significant, which could reduce and prevent the risk of severe bleeding such as intracranial. The incidence of thrombus in the stent was not increased, and the quality of life of the patient was significantly improved.